ERBB2 and esophageal adenocarcinoma: HER2-positivity is reported in other carcinomas, most notably gastric and oesophageal adenocarcinomas.1–19 A large phase III trial employing trastuzumab, directed against the HER2 protein, has been conducted for advanced gastric carcinomas showing clinical benefit (ToGA trial20).